What question did this study set out to answer?

Evaluate the effectiveness of bimekizumab in patients with moderate to severe hidradenitis suppurativa.

April 3, 2026Clinical and Experimental Dermatology1 citations

Bimekizumab for treatment of moderate to severe hidradenitis suppurativa: A real-world, single centre case series

EPEmily PenderUniversity College Dublin ECEmma CarrollUniversity College Dublin MVMaria-Alexandra VisanSt. Vincent's University Hospital

Key Points

Evaluate the effectiveness of bimekizumab in patients with moderate to severe hidradenitis suppurativa.
Single-center case series
Assess response rates at week 16
Examine previous biologic exposure in patients
Response rates at week 16 are higher than in phase III clinical trials
All patients had previous biologic exposure
Concomitant HS medication may influence results

Abstract

Response rates in this group at week 16 are higher than those seen in phase III clinical trials, despite previous biologic exposure in all patients. While concomitant HS medication may play a role in this higher response rate, bimekizumab is an important treatment option for moderate-to-severe HS.

AI에게 질문

Bookmark

View Full Paper